Atherosclerosis Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of SB-480848 on other circulating biomarkers associated with cardiovascular risk, and evaluate the pharmacokinetics, safety and tolerability of SB-480848 over 12 weeks of once-daily oral dosing. Subjects will first be randomized 1:1 to double-blind atorvastatin 20 mg or 80 mg once daily for a minimum of 3 weeks. Subjects will then be randomized 1:1:1:1 to oral doses of SB-480848 40 mg, 80 mg, 160 mg or placebo once daily for 12 weeks. Blood samples will be collected at various timepoints. Vital signs, electrocardiograms, clinical laboratory safety tests and adverse event assessments will be performed to evaluate the safety and tolerability of SB-480848.
Status | Completed |
Enrollment | 969 |
Est. completion date | September 2006 |
Est. primary completion date | September 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion criteria: - Female subjects must be of non-childbearing potential. - Stable CHD or CHD-risk equivalent. - Must have been on a stable dose of a statin for =4 weeks with LDL <130 mg/dL (3.4 mmol/L) or off statin therapy for =4 weeks with LDL <160 mg/dL (4.1 mmol/L). - On a stable dose of at least one oral antiplatelet agent (e.g., aspirin, clopidogrel, or ticlopidine). Exclusion criteria: - Recent cardiovascular event and / or vascular procedure. - History of difficult to manage dyslipidemia. - Planned cardiac surgery or PCI (percutaneous coronary intervention) or planned major non-cardiac surgery. - Inadequately controlled hypertension. - Poorly controlled diabetes mellitus. - Serum triglycerides >400 mg/dL (4.52 mmol/L). - Recent or ongoing acute infection. - History of chronic inflammatory disease. - Receiving topical, oral, inhaled or injectable corticosteroids. - History of chronic viral hepatitis, or other chronic hepatic disorders. - History of kidney transplant. - History of myopathy or inflammatory muscle disease, or elevated total serum CK (3 x ULN). - Severe heart failure (NYHA class III or IV), or severe left ventricular dysfunction (ejection fraction <30%). - Asthma manifested by bronchospasm in the past 6 months, or currently taking inhaled bronchodilator on regular basis. - History of anaphylaxis, anaphylactoid reactions or severe allergic responses within the past 6 months. - Malignancy within the past 2 years, other than non-melanoma skin cancer. - Current life-threatening condition other than vascular disease that may prevent a subject from completing the study. - QTc interval >440 msec (males) or >450 msec (females). - Alcohol or drug abuse within the past 6 months. - Previous exposure to SB-480848. - Use of an investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication (blinded atorvastatin). |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Argentina | GSK Investigational Site | Buenos Aires | |
Argentina | GSK Investigational Site | Buenos Aires | |
Argentina | GSK Investigational Site | Ciudad Autónoma de Buenos Aires | |
Australia | GSK Investigational Site | Caulfield | Victoria |
Australia | GSK Investigational Site | Geelong | Victoria |
Australia | GSK Investigational Site | Kippa Ring | Queensland |
Bulgaria | GSK Investigational Site | Pleven | |
Bulgaria | GSK Investigational Site | Sofia | |
Bulgaria | GSK Investigational Site | Sofia | |
Bulgaria | GSK Investigational Site | Sofia | |
Canada | GSK Investigational Site | Oakville | Ontario |
Canada | GSK Investigational Site | Ottawa | Ontario |
Canada | GSK Investigational Site | Sainte-Foy | Quebec |
Canada | GSK Investigational Site | Sainte-Foy | Quebec |
Denmark | GSK Investigational Site | Koebenhavn N | |
Estonia | GSK Investigational Site | Tallinn | |
Estonia | GSK Investigational Site | Tallinn | |
Estonia | GSK Investigational Site | Tartu | |
France | GSK Investigational Site | Anzin | |
France | GSK Investigational Site | Bron Cedex | |
France | GSK Investigational Site | Créteil | |
France | GSK Investigational Site | Dommartin-les-Toul | |
France | GSK Investigational Site | Gières | |
France | GSK Investigational Site | Montbrison | |
France | GSK Investigational Site | Montpellier Cedex 5 | |
France | GSK Investigational Site | Pessac cedex | |
France | GSK Investigational Site | Toulouse | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Bochum | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Dresden | Sachsen |
Germany | GSK Investigational Site | Essen | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Goch | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Haag | Bayern |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Kippenheim | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Koeln | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Kuenzing | Bayern |
Germany | GSK Investigational Site | Leipzig | Sachsen |
Germany | GSK Investigational Site | Leipzig | Sachsen |
Germany | GSK Investigational Site | Muenchen | Bayern |
Germany | GSK Investigational Site | Nuernberg | Bayern |
Germany | GSK Investigational Site | Rednitzhembach | Bayern |
Germany | GSK Investigational Site | Rhaunen | Rheinland-Pfalz |
Germany | GSK Investigational Site | Schwerin | Mecklenburg-Vorpommern |
Germany | GSK Investigational Site | Witten | Nordrhein-Westfalen |
Hungary | GSK Investigational Site | Budapest | |
Hungary | GSK Investigational Site | Budapest | |
Hungary | GSK Investigational Site | Debrecen | |
Hungary | GSK Investigational Site | Szeged | |
Hungary | GSK Investigational Site | Szolnok | |
India | GSK Investigational Site | Banglore | |
India | GSK Investigational Site | Hyderabad | |
India | GSK Investigational Site | New Delhi | |
Netherlands | GSK Investigational Site | Den Helder | |
Netherlands | GSK Investigational Site | EDE | |
Netherlands | GSK Investigational Site | Enschede | |
Netherlands | GSK Investigational Site | Haarlem | |
Netherlands | GSK Investigational Site | Hoofddorp | |
Netherlands | GSK Investigational Site | Rotterdam | |
Netherlands | GSK Investigational Site | Sneek | |
Netherlands | GSK Investigational Site | Zeist | |
New Zealand | GSK Investigational Site | Hamilton | |
New Zealand | GSK Investigational Site | Takapuna | |
Pakistan | GSK Investigational Site | Karachi | |
Pakistan | GSK Investigational Site | Karachi | |
Romania | GSK Investigational Site | Bucharest | |
Romania | GSK Investigational Site | Bucuresti | |
Romania | GSK Investigational Site | Targu-Mures | |
Spain | GSK Investigational Site | Alicante | |
Spain | GSK Investigational Site | Barcelona | |
Spain | GSK Investigational Site | Barcelona | |
Spain | GSK Investigational Site | Cáceres | |
Spain | GSK Investigational Site | Madrid | |
Spain | GSK Investigational Site | Madrid | |
Spain | GSK Investigational Site | Madrid | |
Spain | GSK Investigational Site | Madrid | |
Spain | GSK Investigational Site | Madrid | |
Spain | GSK Investigational Site | Móstoles/Madrid | |
Spain | GSK Investigational Site | Oviedo | |
Spain | GSK Investigational Site | Palma de Mallorca | |
Spain | GSK Investigational Site | Quart de Poblet, Valencia | |
Spain | GSK Investigational Site | San Juan De Alicante | |
Spain | GSK Investigational Site | Santiago de Compostela | |
Spain | GSK Investigational Site | Santiago de Compostela/La Coruña | |
Spain | GSK Investigational Site | Sta. Coloma de Gramanet/Barcelona | |
Spain | GSK Investigational Site | Tarrasa, Barcelona | |
United States | GSK Investigational Site | Auburn | Maine |
United States | GSK Investigational Site | Birmingham | Alabama |
United States | GSK Investigational Site | Bryan | Texas |
United States | GSK Investigational Site | Camp Hill | Pennsylvania |
United States | GSK Investigational Site | Chicago | Illinois |
United States | GSK Investigational Site | Chicago | Illinois |
United States | GSK Investigational Site | Cincinnati | Ohio |
United States | GSK Investigational Site | Fort Lauderdale | Florida |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Indianapolis | Indiana |
United States | GSK Investigational Site | Jacksonville | Florida |
United States | GSK Investigational Site | Lacombe | Louisiana |
United States | GSK Investigational Site | New York | New York |
United States | GSK Investigational Site | Norfolk | Virginia |
United States | GSK Investigational Site | Northport | Alabama |
United States | GSK Investigational Site | Oklahoma City | Oklahoma |
United States | GSK Investigational Site | Pembroke Pines | Florida |
United States | GSK Investigational Site | Philadelphia | Pennsylvania |
United States | GSK Investigational Site | Phoenix | Arizona |
United States | GSK Investigational Site | Richmond | Virginia |
United States | GSK Investigational Site | Salt Lake City | Utah |
United States | GSK Investigational Site | San Antonio | Texas |
United States | GSK Investigational Site | Slidell | Louisiana |
United States | GSK Investigational Site | Spring Valley | California |
United States | GSK Investigational Site | Statesville | North Carolina |
United States | GSK Investigational Site | Torrance | California |
United States | GSK Investigational Site | Tucson | Arizona |
United States | GSK Investigational Site | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States, Argentina, Australia, Bulgaria, Canada, Denmark, Estonia, France, Germany, Hungary, India, Netherlands, New Zealand, Pakistan, Romania, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | On treatment sustained inhibition of plasma Lp-PLA2 activity. | 12 Weeks | ||
Secondary | Difference in dose-dependent effects of SB-480848 on plasma Lp-PLA2 activity, other biomarkers, and safety. | 12 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05052918 -
The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Completed |
NCT05906797 -
Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis.
|
N/A | |
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Suspended |
NCT02932176 -
Machine Learning for Handheld Vascular Studies
|
||
Recruiting |
NCT05158257 -
Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity
|
N/A | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Recruiting |
NCT06230406 -
T-Mem GEne in Atherosclerosis
|
||
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT00382564 -
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
|
N/A | |
Recruiting |
NCT02894931 -
Effects of Dietary Interventions on Serum and Macrophage Atherogenicity
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|
||
Completed |
NCT03393377 -
Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination
|
N/A | |
Completed |
NCT02268513 -
Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
|
||
Completed |
NCT02224339 -
New Technologies to Determine Carotid Plaque Vulnerability
|
||
Completed |
NCT02116829 -
Is There Room for Butter in a Healthy Diet?
|
N/A | |
Not yet recruiting |
NCT01923012 -
Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis
|
Phase 2 |